Literature DB >> 22507598

Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea.

Mehran Ghoreishi1, Cristián Vera Kellet, Jan P Dutz.   

Abstract

Morphea is an autoimmune sclerotic skin disease of unknown pathogenesis. As type 1 interferons (IFN) have been implicated in the pathogenesis of systemic sclerosis, we proposed that type 1 IFN promote localized inflammation and fibrosis in morphea. To investigate the expression of the type 1 IFN-inducible protein myxovirus A (MxA) and the presence of plasmacytoid dendritic cells (pDC) in lesions of morphea, lesional skin of 10 patients with morphea was examined by immunohistochemistry for the presence of the type 1 IFN-inducible protein, myxovirus A (MxA), and the pDC markers, CD123 and BDCA-2, and was compared with lesional skin of cutaneous lupus erythematosus, lichen planus and keloid. Lesional and non-lesional morphea skin was compared. MxA was expressed in the epidermis as well as the reticular dermis and subcutis in morphea. pDCs were abundant around vessels and between fibrous bundles. Non-lesional biopsies demonstrated little or no expression of MxA and pDC markers. Keloid showed minimal expression of MxA and pDC markers. We demonstrate the expression of type 1 IFN-related protein MxA and plasmacytoid DCs in lesional but not in non-lesional biopsies of morphea. These findings suggest a potential role for type 1 interferons in the pathogenesis of morphea.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507598     DOI: 10.1111/j.1600-0625.2012.01475.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  8 in total

Review 1.  The Immunogenetics of Morphea and Lichen Sclerosus.

Authors:  Pooya Khan Mohammad Beigi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the Morphea in Adults and Children cohort.

Authors:  Heidi Jacobe; Chul Ahn; Frank C Arnett; John D Reveille
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

Review 3.  The influence of interferon on healthy and diseased skin.

Authors:  Grace A Hile; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Cytokine       Date:  2018-12-06       Impact factor: 3.861

Review 4.  The role of dendritic cells and regulatory T cells in the pathogenesis of morphea.

Authors:  Agnieszka Osmola-Mańkowska; Ewa Teresiak-Mikołajczak; Aleksandra Dańczak-Pazdrowska; Michał Kowalczyk; Ryszard Żaba; Zygmunt Adamski
Journal:  Cent Eur J Immunol       Date:  2015-04-22       Impact factor: 2.085

5.  Effects of UVA1 Phototherapy on Expression of Human Endogenous Retroviral Sequence (HERV)-K10 gag in Morphea: A Preliminary Study.

Authors:  Michał Jacek Kowalczyk; Ewa Teresiak-Mikołajczak; Aleksandra Dańczak-Pazdrowska; Ryszard Żaba; Zygmunt Adamski; Agnieszka Osmola-Mańkowska
Journal:  Med Sci Monit       Date:  2017-01-28

6.  Expression of selected genes of dendritic and Treg cells in blood and skin of morphea patients treated with UVA1 phototherapy.

Authors:  Agnieszka J Osmola-Mańkowska; Ewa Teresiak-Mikołajczak; Michał J Kowalczyk; Ryszard W Żaba; Zygmunt Adamski; Aleksandra Dańczak-Pazdrowska
Journal:  Arch Med Sci       Date:  2018-02-21       Impact factor: 3.318

Review 7.  The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases.

Authors:  Jessica L Turnier; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2020-12-01       Impact factor: 5.422

8.  Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.

Authors:  Alex Pellerin; Karel Otero; Julie M Czerkowicz; Hannah M Kerns; Renée I Shapiro; Ann M Ranger; Kevin L Otipoby; Frederick R Taylor; Thomas O Cameron; Joanne L Viney; Dania Rabah
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.